Cbl-b-IN-2

Cbl-b-IN-2

• CAS Number: 2503325-21-9
• UNSPSC Description: Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent[1].
• Target Antigen: E3 Ligase Ligand-Linker Conjugates
• Type: Reference compound
• Related Pathways: PROTAC
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/cbl-b-in-2.html
• Solubility: DMSO : 140 mg/mL (ultrasonic)
• Smiles: O=C1N(C2=CC=CC(C3(CC4=NN=CN4C)COC3)=C2)CC5=C1C=C(CN6C[C@@H](C)C(F)(F)CC6)C=C5C(F)(F)F
• Molecular Weight: 575.57
• References & Citations: [1]Arthur T. Sands, et al. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus. Patent WO 2020210508A1.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported